# A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

> **NCT01033123** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 41 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** BSI-201

## Key facts

- **NCT ID:** NCT01033123
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033123, "A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01033123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*